This episode was recorded on Monday, March 30, 2020.

Claim credit here: https://ce.mayo.edu/covid19podcast

Guest:  Matthew P. Van Cuyk, Pharm.D., R.Ph. 

Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006) 

Should we be using ibuprofen to treat patients with COVID-19? Does this fall into the modifiable risk category? Dr. Matthew Van Cuyk breaks down recent events and literature around ibuprofen use in patients with COVID-19. 

Deeper Dive:

1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine. March 2020. https://doi.org/10.1016/S2213-2600(20)30116-8
2. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
3. ASHP Coronavirus Resource Center: https://www.ashp.org/Pharmacy-Practice/Resource-Centers/Coronavirus
4. Assessment of Evidence for COVID-19-Related Treatments: Updated 3/27/2020

For the most up to date COVID-19 information:

• CDC: https://www.cdc.gov/coronavirus/2019-ncov/index.html
• WHO: https://www.who.int/emergencies/diseases/novel-coronavirus-2019